Nuclear Imaging is the branch of medical imaging that uses radioactive material to diagnose the severity of the diseases such as cancer, cardiovascular
disease, gastrointestinal, endocrine, neurological disorders and other abnormalities within the body.
Nuclear imaging procedures are non-invasive and painless medical test that helps physician diagnose and evaluate medical condition.
Recently, GE Healthcare launched a new product called GENtrace, which is a small cyclotron to produce isotope fluorine-18 (F-18) which forms the base for
PET tracer manufacturing. The device is easy to use, very simple, do more automated steps and could be operated by nuclear medicine technician.
It has been found that more prostate cancer has been detected by. A new molecular imaging agent was demonstrated in Society of Nuclear Medicine and
Molecular Imaging (SNMMI) to find prostate cancer on tissues by locking in on the prostate specific membrane antigen (PSMA) enzyme. By this agent, one can
detect prostate cancer cells that have metastasized to bone, which is a most difficult area to evaluate. The radiotracer combines with a radioactive
material and an antibody called minibody. Mini-body contains anti-PSMA qualities. The radiotracer, called Zr-89 Df-IAB2M (IAB2M) imaged faster than the
full antibody (J591) that targets PSMA. The particles which are emitted, detected by positron emission tomography (PET), which then creates a computerized
image of the activity of the agent within the body.
Browse Full Report@ http://www.futuremarketinsights.com/reports/nuclear-imaging-devices-market